Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00141570 · ClinicalTrials.gov registry record · Phase 2
Study of the Efficacy of ESTRATEST® H.S. Tablets in Relieving Menopausal Symptoms in Estrogenized Postmenopausal Women
A Phase 2 study of Menopause, sponsored by Solvay Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 350
- Enrollment target
- 20
- Study locations
NCT00141570: Completed Phase 2 study of Menopause, sponsored by Solvay Pharmaceuticals.
NCT00141570 is a Phase 2 study of Menopause that has completed, run by Solvay Pharmaceuticals. The registered enrollment target is 350 participants, below the 9,388-participant average among 54 other Menopause trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00141570, a Phase 2 study of Menopause, has completed, sponsored by Solvay Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 350 participants
- Enrollment target
- 20
- Study locations
Study Summary
To determine whether treatment with ESTRATEST® H.S. Tablets is superior to treatment with esterified estrogens tablets
Conditions Studied
Interventions
- DRUG esterified estrogens 0.625 mg and methyltestosterone 1.25 mg
Study Locations (20)
California
- Site 68 - Carmichael
- Site 55 - Encinitas
- Site 6 - San Diego
- Site 45 - Santa Rosa
- Site 25 - Walnut Creek
Connecticut
- Site 1 - Groton
- Site 54 - Hartford
- Site 30 - Trumbull
- Site 34 - Waterbury
Alabama
- Site 66 - Huntsville
- Site 57 - Mobile
- Site 46 - Montgomery
Florida
- Site 10 - Aventura
- Site 73 - Fort Myers
- Site 51 - Leesburg
Arizona
- Site 29 - Phoenix
- Site 15 - Tucson
Arkansas
- Site 3 - Jonesboro
- Site 22 - Little Rock
Colorado
- Site 26 - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2004-06 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
What the finished NCT00141570 record still lists
NCT00141570 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, below the 9,388-participant average among 54 other Menopause trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Menopause appearing as the primary indexed condition, and to 1 intervention - of which esterified estrogens 0.625 mg and methyltestosterone 1.25 mg is the first listed.
NCT00141570 names 20 study sites across 7 states, led by California, Connecticut, Alabama.
Frequently Asked Questions
What is clinical trial NCT00141570 about?
NCT00141570 is a clinical study titled "Study of the Efficacy of ESTRATEST® H.S. Tablets in Relieving Menopausal Symptoms in Estrogenized Postmenopausal Women". To determine whether treatment with ESTRATEST® H.S. Tablets is superior to treatment with esterified estrogens tablets
What is the current status of trial NCT00141570?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 350 participants. The study started on 2004-06. Estimated completion is 2007-06.
What conditions does trial NCT00141570 study?
This clinical trial studies the following conditions: Menopause.
What interventions are being tested in trial NCT00141570?
The interventions under investigation include: esterified estrogens 0.625 mg and methyltestosterone 1.25 mg (DRUG).
Who is sponsoring clinical trial NCT00141570?
This trial is sponsored by Solvay Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00141570 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Menopause
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00141570's enrollment target sits among peer trials
350 7th of 54 higher than 48 of 54 other Menopause trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Menopause trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Anabolic Effect of Testosterone on Pelvic Floor Muscles
RECRUITING · Phase 2
-
Effects of Hemp-Derived Cannabinoids on Menopause Symptoms
RECRUITING · Phase 2
-
Impact of Cannabinoids on Menopause Symptoms
RECRUITING · Phase 2
-
PhytoSERM to Prevent Menopause Associated Decline in Brain Metabolism and Cognition
ACTIVE NOT RECRUITING · Phase 2
-
Hormone Replacement in Menopausal Women With Epilepsy
COMPLETED · Phase 2
-
A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia